47538 Federal Register / Vol. 82, No. 196 / Thursday, October 12, 2017 / Notices 

SUPPLEMENTARY INFORMATION: The 

following represents the intellectual 

property is to be licensed under the 

prospective agreement: HHS Ref. No. E– 

181–2016/0, including provisional 

patent applications 62/396,613 filed 

September 19, 2016 entitled ‘‘Zika Virus 

Vaccines’’, and all continuing U.S. and 

foreign patents/patent applications for 

the technology family, to PaxVax Inc. 

All rights in these inventions have 

been assigned to the Government of the 

United States of America. 

The prospective Exclusive Patent 

License territory may be worldwide and 

the field of use may be limited to: 

‘‘Development and use of DNA-based 

vaccines expressing virus-like particle 

antigens comprising Zika virus 

membrane and/or envelope proteins for 

prevention of Zika virus infection in 

humans.’’ 

Since 2015, Zika virus (ZIKV) 

outbreaks have had a significant effect 

on global public health. The mosquitoborne disease, which causes several 

congenital abnormalities in the 

developing fetus, as well as other 

neurological disorders in infected 

individuals has no approved vaccine to 

treat or prevent infection. To address 

this critical need, several approaches are 

being explored for a vaccine against 

ZIKV infection in priority populations 

including women of child-bearing age 

and their partners. 

Many entities, governmental, 

academic, and commercial, are actively 

pursuing development of ZIKV vaccines 

each using a different approach to 

address this public health need. The 

U.S. Government is coordinating its 

vaccine development response to ZIKV 

and has published this plan at https:// 

www.phe.gov/Preparedness/planning/ 

Pages/zika-white-paper.aspx. 

Vaccine development approaches for 

ZIKV include but are not limited to 

inactivated virus (dead virus), live 

attenuated virus (weakened virus), 

recombinant viral vectors (weakened 

virus with target genes added), and 

subunit (portion of a virus) as well as 

mRNA- and DNA-based (gene-targeted). 

These various strategies provide 

multiple redundancies, expanded 

choice, and ensure short and long term 

maximal benefits to the public. 

The subject invention relates to the 

use of nucleic acid molecules encoding 

Zika virus (ZIKV) proteins that when 

introduced in a cell produces 

noninfectious virus-like particles (VLPs) 

capable of eliciting a protective immune 

response against viral infection. More 

specifically, the subject vaccine is a 

DNA-based candidate encoding a 

polypeptide of a ZIKV membrane and 

envelope proteins that when expressed 

results in production of noninfectious 

VLPs that generate protective 

neutralizing antibodies against ZIKA 

infection. The vaccine, which is based 

on a similar vaccine developed for the 

related West Nile virus, is currently 

undergoing clinical trial evaluation. The 

subject invention has been advertised in 

the Federal Register and published on 

12 December 2016. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective Exclusive Patent 

License will be royalty bearing and may 

be granted unless within thirty (30) days 

from the date of this published notice, 

the NIAID receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404. 

Complete applications for a license in 

the prospective field of use that are 

timely filed in response to this notice 

will be treated as objections to the grant 

of the contemplated Exclusive Patent 

License. Comments and objections 

submitted to this notice will not be 

made available for public inspection 

and, to the extent permitted by law, will 

not be released under the Freedom of 

Information Act, 5 U.S.C. 552. 

Dated: October 5, 2017. 

Suzanne Frisbie, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2017–21986 Filed 10–11–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences Special Emphasis 

Panel; Review of Support of Competitive 

Research (SCORE) Award Applications. 

Date: November 8, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Courtyard by Marriott Chevy Chase, 

5520 Wisconsin Avenue, Chevy Chase, MD 

20815. 

Contact Person: Manas Chattopadhyay, 

Ph.D., Scientific Review Officer, Office of 

Scientific Review, National Institute of 

General Medical Sciences, National Institutes 

of Health, Building 45, Room 3An12N, 45 

Center Drive, Bethesda, MD 20892, 301–827– 

5320, manasc@mail.nih.gov. 

Name of Committee: National Institute of 

General Medical Sciences Special Emphasis 

Panel; Review of NIH Pathway to 

Independence Award K99/R00 Applications. 

Date: November 16, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Garden Inn Bethesda, 7301 

Waverly Street, Bethesda, MD 20814. 

Contact Person: Robert Horowits, Ph.D., 

Scientific Review Officer, National Institute 

of General Medical Sciences, National 

Institutes of Health, 45 Center Drive, Room 

3An.18, Bethesda, MD 20892–6200, 301– 

594–6904, horowitr@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives; 93.859, 

Biomedical Research and Research Training, 

National Institutes of Health, HHS) 

Dated: October 5, 2017. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–21990 Filed 10–11–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Board of Scientific 

Counselors, NIDCD. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 196 / Thursday, October 12, 2017 / Notices 47539 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

NATIONAL INSTITUTE ON DEAFNESS 

AND OTHER COMMUNICATION 

DISORDERS, including consideration of 

personnel qualifications and 

performance, and the competence of 

individual investigators, the disclosure 

of which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Board of Scientific 

Counselors, NIDCD. 

Date: November 6, 2017. 

Open: 8:00 a.m. to 8:15 a.m. 

Agenda: Reports from the institute staff. 

Place: National Institutes of Health, Porter 

Neuroscience Research Center, Room 610, 

Building 35A, Convent Drive, Bethesda, MD 

20892. 

Closed: 8:15 a.m. to 3:45 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Institutes of Health, Porter 

Neuroscience Research Center, Room 610, 

Building 35A, Convent Drive, Bethesda, MD 

20892. 

Contact Person: Andrew J. Griffith, Ph.D., 

MD, Director, Division of Intramural 

Research, National Institute on Deafness and 

Other Communication Disorders, 35A 

Convent Drive, GF 103, Rockville, MD 20892, 

301–496–1960, griffita@nidcd.nih.gov. 

Any member of the public interested in 

presenting oral comments to the committee 

may notify the Contact Person listed on this 

notice at least 10 days in advance of the 

meeting. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. In addition, any interested person 

may file written comments with the 

committee by forwarding their statement to 

the Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

business or professional affiliation of the 

interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http://

www.nidcd.nih.gov/about/groups/bsc/, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.173, Biological Research 

Related to Deafness and Communicative 

Disorders, National Institutes of Health, HHS) 

Dated: October 5, 2017. 

Sylvia L. Neal, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–21974 Filed 10–11–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences Special Emphasis 

Panel. 

Date: November 16, 2017. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Natcher Building, Room 3An12N, 45 Center 

Drive, Bethesda, MD 20892. 

Contact Person: Lisa A. Dunbar, Scientific 

Review Officer, Office of Scientific Review, 

National Institute of General Medical 

Sciences, National Institutes of Health, 45 

Center Drive, Room 3AN12, Bethesda, MD 

20892, 301–594–2849, dunbarl@mail.nih.gov. 

Name of Committee: National Institute of 

General Medical Sciences Special Emphasis 

Panel; Review of R13 Conference Grant 

Applications. 

Date: November 17, 2017. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Natcher Building, Room 3An.12N, 45 Center 

Drive, Bethesda, MD 20892. 

Contact Person: Rebecca H. Johnson, 

Scientific Review Officer, Office of Scientific 

Review, National Institute of General Medical 

Sciences, National Institutes of Health, 

Natcher Building, Room 3AN18C, Bethesda, 

MD 20892, 301–594–2771, johnsonrh@

nigms.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives; 93.859, 

Biomedical Research and Research Training, 

National Institutes of Health, HHS) 

Dated: October 5, 2017. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–21991 Filed 10–11–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

National NeuroAIDS Tissue Consortium. 

Date: November 7, 2017. 

Time: 3:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: David M. Armstrong, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center/ 

Room 6138/MSC 9608, 6001 Executive 

Boulevard, Bethesda, MD 20892–9608, 301– 

443–3534, armstrda@mail.nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

PsychENCODE. 

Date: November 8, 2017. 

Time: 1:00 p.m. to 5:00 p.m. 


asabaliauskas on DSKBBXCHB2PROD with NOTICES